GMRx2 Placebo Controlled Trial (PCT)

The GMRx2-ICTU team is proud to setup 10 primary care sites in the UK to for the GMRx2-Placebo Controlled Trial (PCT) study.

This phase III trial will investigate George Medicines proprietary triple low-dose combination GMRx2 pill for the treatment of hypertension compared to placebo.

This international multi-centered study (US, Australia, Sri Lanka and Nigeria) hopes to recruit over 300 patients globally with approximately 100 patients from the UK. 

The GMRx2-ICTU team have also been tasked to set up three sites in Nigeria for the PCT study in the coming weeks.



For further information regarding our services and how we can collaborate, please contact our team